Back
PTC Therapeutics, Inc. (PTCT)
BiotechnologyPTCT · NASDAQ NMS - GLOBAL MARKET · USD
New to investing? How to read this page →$73.42
+3.42%Weekly undervalued picks
Price · 1 year
Loading live analysis…
Loading analysis…
Intrinsic Investor is for research and education only. Not financial advice.
Key metrics
EPS
$7.73
ROE
Gross margin
38.3%
Debt/Equity
Revenue growth
-76.8%
P/B ratio
Beta
Forward P/E
PTC Therapeutics, Inc. — company intelligence
Earnings surprises
Q2 2026$0.92 vs $0.43 est+116.4%
Q1 2026$-0.03 vs $-0.48 est+93.7%
Q4 2025$-1.67 vs $0.04 est-4460.3%
Q3 2025$0.20 vs $-1.40 est+114.3%
Analyst consensus · 21 analysts
17 Buy3 Hold1 Sell
Updated Jul 10, 2026
Insider activity · 90 days
4 buys29 sellsnet -128,300 shares
Klein Matthew B.Sell 10,292 · Aug 4, 2026
Sollie-Zetlmayer Hege ElisabethBuy 2,000 · Jul 28, 2026
Sollie-Zetlmayer Hege ElisabethBuy 1,738 · Jul 28, 2026
Recent SEC filings
4 — Insider transaction reportAug 21, 2026
4 — Insider transaction reportAug 19, 2026
8-K — Material event reportAug 13, 2026
Latest news
Barclays Maintains Overweight on PTC Therapeutics, Raises Price Target to $122 — Benzinga · 1w ago
PTC Therapeutics Expands Rare Disease Portfolio with 'Unique Opportunity' — Benzinga · 1w ago
Wells Fargo Maintains Overweight on PTC Therapeutics, Raises Price Target to $109 — Benzinga · 1w ago
AI Valuation Narrative
Generates a short bull / bear / catalyst summary from the analytics we already computed. No target prices. Research tool, not investment advice.
Explore more
Peers & similar stocks
Quick links to related tickers for research.
Weekly undervalued picks
Get 3 new value ideas and the fair-value math behind them every week. One email, unsubscribe anytime.
Free. No spam. We only email once per week.
Data is provided "as-is" and may be delayed or incomplete. Intrinsic Investor is for education only and is not investment advice.